Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation

心脏移植后原发移植物功能障碍风险的免疫遗传学分析 对于美国大约25万患有终末期心力衰竭的人来说，心脏 移植(HT)仍然是治疗的金标准。尽管长期存活良好，但早期死亡 由于感染、排斥反应和原发移植物功能障碍(PGD)，移植物的存活率仍然很高。特别是，pgd是一种 新的同种异体移植物的急性失效导致血流动力学不稳定和 末梢器官低灌注症。因此，我们在此建议以有趣的初步数据为基础，表明 血浆中作为浆细胞样树突状细胞表面受体的蛋白CLEC4C的水平 (PDCs)，移植前患者移植前较高，随后在移植后发展为PGD。具体来说，我们将 集成免疫分析、pDC和PBMC的单细胞测序以及单细胞蛋白质组学 分离pDC以验证pDC在羟色胺中数量和功能丰富的假说 发生PGD的受者。这项研究有可能在护理中识别临床相关的生物标记物 这可能有助于阐明PGD的潜在分子机制。

Immunogenetic Profiling for Risk of Primary Graft Dysfunction after Heart Transplantation For the approximately 250,000 people in the United States living with end-stage heart failure, heart transplantation (HT) remains the gold standard therapy. Despite excellent long-term survival, early mortality remains high as a result of infection, rejection, and primary graft dysfunction (PGD). PGD, in particular, is a devastating complication of HT in which acute failure of the new allograft leads to hemodynamic instability and end-organ hypoperfusion. Thus, we propose herein to build upon interesting preliminary data suggesting that plasma levels of CLEC4C, a protein that serves as a cell surface receptor for plasmacytoid dendritic cells (pDCs), are higher prior to transplant in patients who subsequently develop PGD after HT. Specifically, we will integrate immune profiling, single cell sequencing of pDCs and PBMCs, and single cell proteomics in isolated pDCs to test the hypothesis that pDCS are quantitatively and functionally enriched in HT recipient who develop PGD. This study has the potential to identify clinically relevant biomarkers in the care of HT recipients and may help to elucidate the underlying molecular mechanisms of PGD.